Ipsen’s Tazemetostat Trial in Tough Lymphoma Group Withdrawn: What Investors Should Know

Ipsen (GB:0MH6) announced an update on their ongoing clinical study.

Study Overview: Ipsen and Epizyme planned a phase 2 trial (NCT06068881) titled “A Phase 2, Open-label, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Oral Tazemetostat for the Treatment of Adult Participants Age 18 and Over With Relapsed/Refractory Follicular Lymphoma Lacking the EZH2 Gain-of-Function (GOF) Mutation.” The goal was to see how well tazemetostat works, and how safe it is, in adults whose follicular lymphoma has come back or not responded to prior treatment and does not carry a specific EZH2 mutation. This would have helped refine use of an already approved cancer drug in a harder-to-treat patient group, with potential to support broader, more confident prescribing.

Intervention/Treatment: The study focused on tazemetostat, marketed as Tazverik, an oral cancer drug taken as tablets. Participants would have received 800 mg twice a day in ongoing 28‑day cycles. The aim was to shrink tumours or stop them growing while monitoring side effects, to confirm whether this dosing schedule offers meaningful benefit in this specific form of lymphoma.

Study Design: The trial was interventional, single‑arm, and open‑label. All enrolled patients would have been assigned to the same treatment group, with no comparison arm and no blinding of patients or doctors. The primary goal was treatment-focused: to measure tumour response and safety in real-world‑like conditions rather than to compare against placebo or another drug.

Study Timeline: The trial was formally registered in late 2023, but its overall status on the registry is now listed as “withdrawn,” meaning it did not progress as planned. The record received its latest update on 28 January 2026, signaling that the sponsors have recently reviewed or confirmed the cancellation status. No primary completion or final completion dates are provided, which is consistent with a study that was halted before enrolment or meaningful data collection.

Market Implications: For investors, the withdrawal of this study narrows near‑term upside around label-strengthening data for tazemetostat in EZH2‑negative follicular lymphoma. Because Tazverik is already approved in the U.S. for relapsed/refractory follicular lymphoma with or without the EZH2 mutation, the key risk is not loss of existing sales but a slower path to evidence that might have expanded or solidified usage in heavily pretreated patients. The update may modestly dampen sentiment toward Ipsen’s and Epizyme’s lymphoma franchise, especially given rising competition in indolent non‑Hodgkin lymphoma from targeted agents and CD20‑directed combinations. That said, the impact on Ipsen’s overall valuation is likely limited, as this was a single phase 2 effort rather than a pivotal registration study. Investors should watch for any re‑designed trials, partnering moves, or portfolio reprioritisation in hematology as indicators of how management intends to extract value from Tazverik and related assets in a competitive oncology landscape.

The ClinicalTrials.gov entry for this trial has been recently updated to show a withdrawn status, and further details remain available on the ClinicalTrials portal.

To learn more about GB:0MH6’s potential, visit the Ipsen drug pipeline page.